Medicus Pharma Ltd. filed a Form 8-K on November 4, 2026, disclosing under Regulation FD that it issued a press release announcing a non-binding letter of intent related to a potential business combination involving its wholly-owned subsidiary, Skinject, Inc., and an undisclosed special purpose acquisition company.

Key Highlights

  • Non-binding letter of intent: Medicus Pharma disclosed a non-binding letter of intent in connection with a potential business combination of its wholly-owned subsidiary, Skinject, Inc., and an undisclosed SPAC.
  • SPAC identity withheld: According to the filing, the special purpose acquisition company involved in the potential transaction was not identified.
  • Anticipated completion timeline: The filing states that the proposed business combination is anticipated to be completed during the first half of 2027, subject to conditions.
  • Majority ownership intention: The filing references Medicus' intention to retain majority economic and voting ownership of the combined company.
  • Concurrent equity financing contemplated: The filing describes a proposed concurrent equity financing as part of the transaction structure, though specific terms were not disclosed.
  • Regulatory filings anticipated: The filing states that if definitive documentation is reached, Medicus and/or the SPAC anticipate filing a registration statement on Form S-4, including a preliminary proxy statement and prospectus, with the SEC.

Medicus Pharma's Skinject Subsidiary at Center of Potential SPAC Transaction

Medicus Pharma Ltd., whose common shares and warrants trade on the NASDAQ Capital Market under the symbols MDCX and MDCXW respectively, filed a current report disclosing the existence of a non-binding letter of intent involving Skinject, Inc., a wholly-owned subsidiary. According to the filing, the potential counterparty is an undisclosed special purpose acquisition company, and the disclosure was made pursuant to Regulation FD on November 4, 2026.

The filing notes that the anticipated completion of the proposed business combination is targeted for the first half of 2027, subject to multiple conditions. These include the completion of due diligence, execution of definitive agreements, receipt of required board and shareholder approvals, satisfaction of a minimum-cash condition, applicable regulatory filing and registration requirements, and stock exchange listing approval, as described in the filing. The filing also references Medicus' stated intention to retain majority economic and voting ownership of the combined company following any transaction.

The filing identifies Skinject's lead program, SkinJect, as being developed for patients with Gorlin Syndrome, and references a planned registrational study designated SKNJCT-005. Additionally, the filing references Medicus' other pipeline assets, including Teverelix and a co-development arrangement with Pfizer related to CD228V across indications including melanoma, squamous non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal cancer. The filing characterizes statements regarding timing, structure, and anticipated benefits of the transaction as forward-looking statements subject to the company's cautionary language and applicable risks described in its annual report on Form 10-K for the year ended December 31, 2025.

What Was Disclosed

Medicus Pharma Ltd. filed a Form 8-K on November 4, 2026, under Regulation FD, disclosing a non-binding letter of intent for a potential business combination of its subsidiary Skinject, Inc. with an undisclosed SPAC, with completion anticipated in the first half of 2027.